All
New dawn of GA management requires renewed attention to imaging
March 18th 2024It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).
COPHy 2024: Should all patients with idiopathic intracranial hypertension have a lumbar puncture?
March 16th 2024Andrew G. Lee, MD, outlines his stance on whether all patients with idiopathic intracranial hypertension should have a lumbar puncture, emphasizing clinical judgment and treatment strategies.
Intraocular inflammation: A major risk factor resulting from use of anti-complement agents for GA
March 15th 2024The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.
Regeneron announces publication of one-year results from PULSAR and PHOTON trials
March 10th 2024Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).